← Leaderboards
Adam Golebiowski
Oncoarendi Therapeutics, Llc
$1,060,293
Attributed
$1,813,003
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,813,003 · 2
By mechanism
R44$1,505,420 · 1
R43$307,583 · 1
Top collaborators
- Reynold Alexander Panettieri1 shared
Most similar at Oncoarendi Therapeutics, Llc
Same institution · by research overlap
- Stanislaw Pikul$112,500
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultAffectAnalogAnimal ModelAttenuatedBinding ProteinsBiologicalCardiacCellular AssayCharacteristicsChronicClinical DevelopmentClinical EffectCollagen Type IConnective Tissue Growth FactorDiagnosisDoseDrug KineticsEtiologyExtracellular Matrix ProteinsFda ApprovedFibroblastsFibrosisActins
Grant awards (3)
Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF)$66,458
R43 · FY2025 · HL · contact PI
Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF)$241,125
R43 · FY2024 · HL · contact PI
Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma$1,505,420
R44 · FY2018 · HL · contact PI